A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether IMC-A12 or IMC-1121B (ramucirumab) with
Mitoxantrone and Prednisone is effective in the treatment of metastatic androgen- independent
prostate cancer (APIC).